Related posts
Nasdaq enters correction, Trump tariffs whiplashTrump tariff war triggers sell-offMarkets sink on Trump tariff fearsThis summary was created by AI, based on 50 opinions in the last 12 months.
Manulife Financial (MFC) has garnered significant attention recently with an optimistic outlook from various experts. Many emphasize the company's solid performance, particularly in Asia, and view its diversified offerings as a competitive advantage. Analysts note that the business has effectively turned around, shedding problematic long-term care liabilities, which has positively impacted its stock price. Furthermore, with rising interest rates, there is an expectation for continued growth and dividend increases, positioning MFC favorably in the market. However, some experts recommend caution, indicating that the stock may be approaching full valuation and suggesting that investors consider entering on pullbacks or market dips.
Markets are tough and can be counter-intuitive. Great beat, and the sector is sheltered from tariffs. Free of negative surprises, unlike SLF. Street models 12.5% EPS growth, trading at 9.34x -- cheaper and more compelling than banks.
The answer could be that the good news was already baked into the stock. He'd take it as a really good sign that it's actually up in the past week of a really tough market. More to go, but doesn't go in a straight line. He's long this one.
A year it ago, it traded at a dirt cheap 6-7x PE. Many thought it was left for dead with bad insurance contracts. In Dec. 2023, they sold a lot of those contracts at a decent price. That's when he entered this. But he recently sold this to buy TD (which has more upside).
Good growth in Asia. Asset management becoming a more important part of the business for all lifecos. Probably trading at higher end of historical levels. More room to go. Solid holding as long as it continues to execute. Yield is relatively attractive, increases over time.
Great performance in 2024 with good dividend yield. Does not own shares. Good growth prospects ahead. Would recommend buying on weakness.
Likes it. Globally diversified. Slightly better dividend than SLF right now, though he likes both names. Also slightly cheaper than SLF, so that's why MFC is in his portfolio.
A lifeco, but also offers investment products. Solid, dependable.
He held this a long time, patiently. Shares finally broke above $28 last year after a long repair period. There remains upside as it raises its dividend and has diversified sales in North America and Asia.
All the insurance names, both in Canada and the US, continue to work. If interest rates do, in fact, go higher, that will only be beneficial for lifecos and other insurers. The chart looks fantastic. Good run, so there is some weakening in the intermediate term.
If a long-term holding, best thing you can do is sit on your hands and do nothing except participate in the DRIP program. Especially if he's right on the broader call of rates being 8-10% in the secular bear market of 2030-40, should be a big tailwind for insurers.
Great business, especially with current interest rates. Would be top insurance pick in Canada. Excellent business with strong management team.
It is one non-bank financial company that keeps on going and going. Insurance companies actually do better when longer term interest rates go up and are one of the better investments when this happens. He owns it in the value momentum strategy fund and it has the potential to expand internationally.
The CEO, retiring next year, is doing a fine job, selling unprofitable product lines, and growth resumed in Hong Kong. MFC is now fully valued. She owns another insurer, though.
Really nice footprint in Asia. Its products still resonate with consumers, despite deflationary situation in China. He adds on pullbacks.
No, you can never do that. Remember that MFC plunged during 2008 because it got into all kinds of trouble. Today, management has learned a lot from that. He sees big upside in their insurance, US and Asian operations. Still offers decent value and dividend growth. However, insurance companies are prone to serious slides if they make a bad misjudgement.
It has been breaking out of its 10 year chart. The legacy issues have been addressed. It is having success in Asia and the wealth management field. Close to 45% of MFC's business is in Asia.
Manulife Financial is a Canadian stock, trading under the symbol MFC-T on the Toronto Stock Exchange (MFC-CT). It is usually referred to as TSX:MFC or MFC-T
In the last year, 42 stock analysts published opinions about MFC-T. 27 analysts recommended to BUY the stock. 3 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Manulife Financial.
Manulife Financial was recommended as a Top Pick by on . Read the latest stock experts ratings for Manulife Financial.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
42 stock analysts on Stockchase covered Manulife Financial In the last year. It is a trending stock that is worth watching.
On 2025-03-14, Manulife Financial (MFC-T) stock closed at a price of $41.825.
Really likes. Attractive valuation. Down ~11% from highs last November. Pretty nice dividend of 4.3%. Holding above the 200-day MA, which is moving upwards. Insurance space gives you decent growth with protectiveness of the dividend.